Repair damaged brain tracts with noninvasive, image-guided, personalized TMS therapy, and with the ability to also focally deliver drugs and gene payloads anywhere in the head
NeurTX is developing a noninvasive, office-based, MRI-guided TMS for focal regeneration and/or myelination of damaged brain tracts, with real-time monitoring of location, dose and response.
The same system may be used to tomographically deliver drugs and and genes across the blood Brain Barrier (BBB).
NeurTX enables image guided, selective, deep, focused therapy for entire tracts and may enable treatment for a range of mood, thought, development, cognition, movement traumatic injury and substance use disorders.
The NeurTX product is not approved by FDA at this time. By United States law, the device portrayed herein and the information included in this presentation are limited to investigational use only.
Unlike existing TMS systems, NeurTX will, for the first time, enable precise and focal delivery of tailored and optimized pulse sequences at desired locations, and measure the impact of therapy on intended biomarkers. This will enable treatment panning, tomographic delivery, real-time treatment monitoring and follow-up assessment, all in one system in an office or clinic setting. It will also facilitate, finally, a bioscience-based paradigm for neurotherapy and mental health therapy
NeurTX is being spun-out from Weinberg Medical Physics (WMP), a medical device incubator located in Rockville, MD. WMP has expertise in medical imaging applications. Representative successes include:
• Developed medical imaging devices used by millions of people.
• FDA-cleared multiple devices for human use
• Licensed numerous patents to companies; sold medical device patent to Philips Medical
• Designed, built and licensed MRI system that has attained FDA clearance for guided therapy applications
WMP has previously launched successful companies, including: Promaxo, Radialis Medical, Brain Biosciences, and Longmile